News - Asia-Pacific, Otsuka

Filter

Current filters:

Asia-PacificOtsuka

Popular Filters

Otsuka’s Samsca, first ADPKD therapy, approved in Japan

25-03-2014

Japanese drugmaker Otsuka Pharmaceutical says it has become the first company in the world to obtain…

Asia-PacificJapanNephrology and HepatologyOtsukaPharmaceuticalRegulationSamsca

Japanese approval for Forxiga and Lonsurf

24-03-2014

Anglo-Swedish drug major AstraZeneca says that Japanese Ministry of Health, Labor and Welfare approved…

Asia-PacificAstraZenecaDiabetesForxigaJapanLonsurfOncologyOno PharmaceuticalOtsukaPharmaceuticalRegulationTaiho Pharmaceutical

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story

16-12-2013

A biotech company’s dream 14-year journey from small start-up to an $886 million takeover bid provided…

Asia-PacificAstex PharmaceuticalsBiotechnologyFinancialInterviewsMergers & AcquisitionsOtsukaUKUSA

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

21-11-2013

Japan’s Otsuka Pharmaceutical (TYO: 4768) and partner Lundbeck (LUN: CO) have received approval from…

Abilify MaintenaAsia-PacificEuropeLundbeckNeurologicalOtsukaPharmaceuticalRegulation

Otsuka's Samsca gains additional indication in Japan

17-09-2013

Japanese drugmaker Otsuka (TYO: 4768) says that its vasopressin V2 receptor antagonist Samsca (tolvaptan)…

Asia-PacificNephrology and HepatologyOtsukaPharmaceuticalRegulationSamscatolvaptan

Japan briefs: Kyowa Kirin debuts Onglyza; Otsuka enrolls TB study, sets up new European

10-07-2013

Japanese drugmaker Kyowa Hakko Kirin (TY: 4151) revealed that it launched the type 2 diabetes drug Onglyza…

Asia-PacificdelamanidEuropeKyowa Hakko KirinMarkets & MarketingOnglyzaOtsukaPharmaceuticalResearch

Taiho Pharma files for approval of cancer drug TAS-102 in Japan

27-02-2013

Japanese drugmaker Taiho Pharmaceutical, a subsidiary of Otsuka (TYO: 4768) says that it submitted an…

Asia-PacificOncologyOtsukaPharmaceuticalRegulationTaiho PharmaceuticalTAS-102

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Claris Lifesciences dips on sale of infusions business

09-12-2012

Indian drugmaker Claris Lifesciences (CLAI: BO) has dipped 4% to 264 rupees, declining over 6% from day's…

Asia-PacificClaris LifesciencesMergers & AcquisitionsMitsui & CoOtsukaPharmaceutical

Otsuka files Abilify, first antipsychotic for major depressive disorder in Japan

04-09-2012

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) has filed an additional indication for Abilify (aripiprazole)…

AbilifyAsia-PacificNeurologicalOtsukaPharmaceuticalRegulation

Japanese filings for Shionogi's metreleptin and Otsuka's tolvaptin

06-08-2012

Japanese drugmaker Shionogi (TYO: 4507) said last week that it has filed a New Drug Application with…

Asia-PacificmetreleptinNephrology and HepatologyOtsukaPharmaceuticalRare diseasesRegulationSamscaShionogitolvaptin

Otsuka sells on Japanese saxagliptin rights to Kyowa Hakko

03-07-2012

Japanese drugmakers Otsuka Pharmaceutical (TYO: 4578) and Kyowa Hakko Kirin (TYO: 4151) have entered…

Asia-PacificBristol-Myers SquibbDiabetesKyowa Hakko KirinLicensingOncologyOtsukaPharmaceuticalResearchsaxagliptin

Additional indication for Otsuka’s Abilify in Japan

22-01-2012

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) said last week that it has received new regulatory…

AbilifyAsia-PacificNeurologicalOtsukaPharmaceuticalRegulation

Otsuka Pharma and UCB re-focus collaboration

16-01-2012

Japan’s Otsuka Pharmaceutical (TYO: 4768) and Belgian drugmaker UCB (Euronext Brussels: UCB) have…

Asia-PacificCimziaImmunologicalsKeppraLicensingNeurologicalOtsukaPharmaceuticalResearchrotigotineUCB

Back to top